Pharmigene, Inc.

TPEX:7595 Stock Report

Market Cap: NT$688.8m

Pharmigene Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Sophia Zhan

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sophia Zhan's remuneration changed compared to Pharmigene's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-NT$93m

Mar 31 2024n/an/a

-NT$83m

Dec 31 2023n/an/a

-NT$73m

Sep 30 2023n/an/a

-NT$61m

Jun 30 2023n/an/a

-NT$48m

Mar 31 2023n/an/a

-NT$46m

Dec 31 2022n/an/a

-NT$43m

Sep 30 2022n/an/a

-NT$40m

Jun 30 2022n/an/a

-NT$37m

Mar 31 2022n/an/a

-NT$30m

Dec 31 2021NT$1mNT$1m

-NT$23m

Compensation vs Market: Insufficient data to establish whether Sophia's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Insufficient data to compare Sophia's compensation with company performance.

CEO

Sophia Zhan (65 yo)

no data

Tenure

NT$1,082,000

Compensation

Ms. Fuhui Zhan, also known as Sophia, is Chairman, Representative Director, GM & CEO of Pharmigene, Inc.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 09:41
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharmigene, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution